Skip to Main Content

We have a new app!

Take the Access library with you wherever you go—easy access to books, videos, images, podcasts, personalized features, and more.

Download the Access App here: iOS and Android


rilonacept (ri-lon-a-sept)



Therapeutic: orphan drugs

Pharmacologic: fusion proteins, interleukin antagonists


Treatment of cryopyrin-associated periodic syndromes (CAPS), including familial cold autoinflammatory syndrome (FCAS) and Muckle-Wells syndrome (MWS).


Modulates cryopyrin by blocking interleukin-1 beta (IL-1β), preventing its interaction with surface receptors. Therapeutic Effects: ↓ inflammatory manifestations of CAPS, including fever, rash, arthralgia, myalgia, fatigue, and conjunctivitis.

Adverse Reactions/Side Effects

Resp: upper respiratory tract infections, cough. Local: injection site reactions. Metab: changes in lipid profile. Neuro: hypoesthesia. Misc: SERIOUS LIFE-THREATENING INFECTIONS, hypersensitivity reactions.


Examination and Evaluation

  • Report any signs of infection, including upper respiratory tract infections. Signs of respiratory infection include cough, fever, nasal congestion, sneezing, runny nose, and sore throat.

  • Assess pain and other variables (range of motion, muscle strength) to document whether this drug is successful in helping manage muscle or joint pain associated with autoinflammatory conditions.

  • Assess any changes in sensation, including decreased sensitivity to touch (hypoesthesia) Perform objective tests including electroneuromyography and sensory testing to document any drug-related neuropathic changes.

  • Monitor signs of hypersensitivity reactions, including pulmonary symptoms (tightness in the throat and chest, wheezing, cough, dyspnea) or skin reactions (rash, pruritus, urticaria). Notify physician or nursing staff immediately if these reactions occur.

  • Assess the subcutaneous injection site for pain, swelling, and irritation. Report prolonged or excessive injection site reactions to the physician.


  • Implement appropriate manual therapy techniques, physical agents, therapeutic exercises, and orthotic/assistive devices to reduce pain, improve function, and augment the effects of drug therapy.

  • Do not apply massage or physical agents (heat, cold, electrotherapeutic modalities) at or near the subcutaneous application site. These interventions can alter drug absorption from subcutaneous tissues.

  • Help patients explore other nonpharmacologic methods to reduce chronic musculoskeletal pain, such as relaxation techniques, exercise, counseling, and so forth.

Patient/Client-Related Instruction

  • Advise patient to guard against infection (frequent hand washing, etc.), and to avoid crowds and contact with persons with contagious diseases.

  • Advise patient that this drug may cause problems in fat metabolism. Remind patient that periodic blood tests may be needed to monitor plasma lipid profile.


Absorption: Absorbed following subcutaneous administration.

Distribution: Unknown.

Metabolism and Excretion: Unknown.

Half-life: Unknown.

|Download (.pdf)|Print

TIME/ACTION PROFILE (improvement in symptoms)

SC within several days unknown unknown


Contraindicated in: Active or chronic infections; OB: May cause fetal harm.

Use Cautiously in: Patients at risk of infections; Lactation: Use cautiously; ...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.